|
|
|
| Clinical effect of Zhengqing Fengtongning combined with low-dose Prednisone Tablets in the treatment of idiopathic membranous nephropathy |
| DENG Tao SHAO Li-yan |
| The Second Department of Nephrology,Jiujiang Traditional Chinese Medicine Hospital,Jiangxi Province,Jiujiang 332000,China |
|
|
|
|
Abstract Objective To explore the clinical effect of Zhengqing Fengtongning combined with low-dose Prednisone Tablets in the treatment of idiopathic membranous nephropathy (IMN).Methods A total of 70 patients with IMN in Jiujiang Traditional Chinese Medicine Hospital from October 2018 to January 2020 were selected and divided into two groups according to the random number table method,with 35 patients in each group.The control group was treated with Prednisone Tablets,and the treatment group was treated with Zhengqing Fengtongning Sustained-release Tablets based on the control group.Treatment lasted nine months in both group.The clinical efficacy,traditional Chinese medicine symptom score and laboratory indexes between the two groups were compared.Results The total effective rate of the treatment group was higher than that of the control group,the difference was statistically significant (P＜0.05).After 3 and 9 months of treatment,the traditional Chinese medicine symptom scores of the treatment group were lower than those of the control group,and the differences were statistically significant (P＜0.05).After 3 and 9 months of treatment,the levels of albumin and fibrinogen in the treatment group were higher than those in the control group,the quantitative levels of 24 h urine protein and triacylglycerol were lower than those in the control group,and the differences were statistically significant (P＜0.05).Conclusion The clinical effect of Zhengqing Fengtongning combined with Prednisone Tablets in the treatment of IMN is remarkable.It can reduce the traditional Chinese medicine symptom score,increase the level of albumin and fibrinogen,and reduce the quantitative level of 24 h urinary protein and triacylglycerol.
|
|
|
|
|
|
| [1] |
刘纯玲，王述蔷，耿晓东，等.利妥昔单抗或他克莫司联合糖皮质激素治疗特发性膜性肾病的疗效比较[J].临床肾脏病杂志，2019，19（6）：421-425.
|
| [2] |
闫晓辉，金刚，王琼，等.特发性膜性肾病患者的临床特点及不同治疗方式的效果[J].西部医学，2019，31（2）：237-240.
|
| [3] |
张连云，王树龙，朱铁锤.黄葵胶囊联合他克莫司和泼尼松治疗特发性膜性肾病的疗效观察[J].现代药物与临床，2017，32（6）：1061-1064.
|
| [4] |
Zeng CH，Chen HM，Wang RS，et al.Etiology and Clinical Characteristics of Membranous Nephropathy in Chinese Patients[J].Am J Kidney Dis，2008，52（4）：691-698.
|
| [5] |
国家中医药管理局.中医病症诊断疗效标准[M].北京：南京大学出版社，1994：42-43.
|
| [6] |
郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社，2002：158-159.
|
| [7] |
薛丕良，牛雯颖，李丽琦，等.雷公藤多苷联合小剂量激素治疗特发性膜性肾病的前瞻性对照研究[J].世界中医药，2019，14（3）：666-669.
|
| [8] |
于艳波，芦珊，娄岩，等.特发性膜性肾病肾小球滤过率下降的相关因素分析[J].中国实验诊断学，2019，23（9）：1589-1592.
|
| [9] |
董洋，阎磊，李纳，等.不同免疫抑制剂联合糖皮质激素治疗特发性膜性肾病的临床疗效比较[J].中华实用诊断与治疗杂志，2017，31（10）：1017-1019.
|
| [10] |
蔡运重,吕杭丽,高祥福.特发性膜性肾病发病机制研究进展[J].浙江临床医学，2019，21（11）：1587-1589.
|
| [11] |
吴成态，李颖霞，丁秀，等.特发性膜性肾病中医药治疗进展[J].江苏中医药，2019，51（10）：87-89.
|
| [12] |
蔡朕，汪蕾，赵文景.参芪地黄汤对血清磷脂酶A2 受体抗体不同滴度的特发性膜性肾病的疗效观察[J].中国临床医生杂志，2019，47（1）：1292-1295.
|
| [13] |
李超.中医治疗特发性膜性肾病探讨[J].中医学报，2018，33（12）：2370-2373.
|
| [14] |
陈生晓,林晓明,甘艳，等.膜性肾病组织中足细胞自噬体数量、自噬相关蛋白表达变化及其意义[J].山东医药，2019，59（8）：73-75.
|
| [15] |
李大勇，郑登勇，唐娟，等.益肾健脾通络汤对特发性膜性肾病患者尿蛋白及凝血功能的影响[J].现代中西医结合杂志，2018，27（36）：4020-4023.
|
|
|
|
